Nanotechnology has made major contributions to breast cancer therapy, using nanoparticles measuring only billionths of a meter to deliver drug molecules directly to the affected tissue.
“A nanoparticle-based drug called Abraxane is being used in clinics to treat breast cancer patients,” says chemical engineering Asst. Prof. Prakash Rai. “However, the disease continues to be a major health concern, with a dire need for better, more effective treatments with lower side effects.”
Rai has been awarded a grant by the National Cancer Institute at the National Institutes of Health (NCI/NIH) totaling more than $725,000 to study a combined, nanotechnology-based diagnostic/therapeutic strategy for the targeted treatment of two subtypes of breast cancer: the human epidermal growth factor receptor 2 positive (HER2+) and the triple-negative breast cancer (TNBC).